Geographic Atrophy

How retina specialists are approaching treatment of GA in clinic.

Positive data from the GALE long-term extension study showed patients developed fewer new scotomatous points with 36 months of both continuous monthly and every-other-month treatment.

Ocugen is developing OCU410 as a 1-time gene therapy for the treatment of geographic atrophy. It utilizes an AAV delivery platform for the retinal delivery of the ROR Related Orphan Receptor A gene.

The company reported that statistically significant data was found supporting ANX007’s ability to provide vision loss protection in patients with geographic atrophy.

Kamuvudine-8, also known as K8, is administered to the back of the eye via a sustained released intravitreal implant.

According to the company, OCU410 utilizes an AAV delivery platform for the retinal delivery of the RORA gene.

The Phase 1/2 study includes a dose-escalation phase of the study featuring 3 cohorts each one receiving either a low, medium, or high dose of OCU410.

Modern Retina’s interview with Aracelis Torres, PhD, MPH sheds light on how real-world insights empower researchers to see trends and develop new strategies, sometimes even new products, to meet the treatment needs of patients.

Since its US launch in September 2023, more than 40,000 avacincaptad pegol intravitreal solution vials have been distributed to physician practices.

The Phase 2 trial tested whether inhibiting microglia with minocycline might help slow GA expansion and its corresponding vision loss.

It is important that the ophthalmic community redouble our efforts in following patients with age-related macular degeneration (AMD) using optical coherence tomography (OCT) to find the early signs of geographic atrophy (GA).

The good news for patients is that GA is transitioning from an untreatable disease to a potentially treatable one with development of new therapies to reduce the growth rate, and use of anti-complement therapies have caused the growth rate of GA lesions to decrease.

OCU410 is a modifier gene therapy candidate being developed for geographic atrophy, an advanced stage of dry age related macular degeneration.

Early detection of the disease is key to optimal patient outcomes

According to the company, its proprietary non-viral gene therapy platform with minimally invasive delivery technology is providing long lasting gene expression and favorable distribution in the retina.

New treatments for geographic atrophy coming down the pike has the potential to change eye care providers' approach to identifying and managing the disease.

Trial will analyze efficacy, safety of AVD-104 versus avacincaptad pegol to treat GA

Sydney M Crago, the editor of Modern Retina, talks with Arshad M Khanani, MD, MA, FASRS, about the expanded efficacy data from the GATHER 2 trial for geographic atrophy (GA).

Allen Ho, MD, FACS, FASRS, will make a presentation at the meeting, to be held virtually on February 3.

The company’s ANX007 global pivotal program in geographic atrophy is expected to start in mid-2024. It is the first pivotal trial to use vision preservation as a primary outcome measure in GA.

In a letter to shareholders, Ricciardi provided updates on Cognition’s 2024 pipeline and expected advances for several diseases.

Catch up on a few of our top stories and ones you may have missed in 2023

The drug is being evaluated on its safety, tolerability and pharmacokinetics of intravitreal single-rising doses and multiple doses as a potential treatment for GA.

Prevent Blindness is providing free geographic atrophy educational resources for patients, care partners and healthcare professionals, including a new episode of its Focus on Eye Health Expert series.

Mohammed Genead, MD, CEO of Aviceda spoke with the Ophthalmology Times team about the company's Phase II/III SIGLEC trial part 1 results, which were shared at this year's American Academy of Ophthalmology meeting.

An anchored matching-adjusted indirect comparison may aid therapeutic decision-making.

Patients treated every other month with the drug also showed a similar decrease in the rate of GA progression compared with sham treatment.

According to the study, pegcetacoplan injection reduced nonsubfoveal GA lesion growth by over 40% (monthly) in Year 3 compared to projected sham in the GALE extension study.

They believe that these phenotypic differences in GA should be considered in different ethnicities because they may have implications in research and in interventions to slow progression of GA.